BENITEC BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.9 USD | -0.58% |
|
-1.29% | +113.62% |
| Apr. 25 | Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors | CI |
| Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
Valuation
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 14.64 | 12.28 | 44.52 | 13.74 | 10.02 | 27.43 | - | - |
| Enterprise Value (EV) 1 | 14.64 | 12.28 | 44.52 | 13.74 | 10.02 | 27.43 | 27.43 | 27.43 |
| P/E ratio | 67.1 x | -1.01 x | -1.27 x | -0.52 x | -0.28 x | -2.8 x | -3.88 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.84 x | 86.5 x | - | 128 x | 86.9 x | - | - | - |
| EV / Revenue | 0.84 x | 86.5 x | - | 128 x | 86.9 x | - | - | - |
| EV / EBITDA | - | - | - | -531,615 x | - | - | - | - |
| EV / FCF | - | - | - | -0.59 x | - | -0.67 x | -0.32 x | -1.02 x |
| FCF Yield | - | - | - | -169% | - | -150% | -309% | -97.6% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 857 | 63 | 462 | 481 | 1,646 | 2,592 | - | - |
| Reference price 2 | 272.1 | 194.9 | 96.37 | 28.59 | 6.088 | 10.58 | 10.58 | 10.58 |
| Announcement Date | 8/29/19 | 10/6/20 | 9/20/21 | 9/2/22 | 9/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.51 | 0.142 | - | 0.1077 | 0.1153 | - | - | - |
| EBITDA | - | - | - | -25.85 | - | - | - | - |
| EBIT 1 | - | -10.14 | - | -26.35 | -29.34 | -44.53 | -68.45 | -40.8 |
| Operating Margin | - | -7,138.43% | - | -24,458.3% | -25,441.88% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | -26.87 | - | - | - | - |
| Net income | - | - | -19.13 | -26.87 | - | - | - | - |
| Net margin | - | - | - | -24,943.26% | - | - | - | - |
| EPS 2 | 4.054 | -192.4 | -75.65 | -55.41 | -21.72 | -3.783 | -2.724 | - |
| Free Cash Flow 1 | - | - | - | -23.26 | - | -41.18 | -84.65 | -26.78 |
| FCF margin | - | - | - | -21,589.69% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/29/19 | 10/6/20 | 9/20/21 | 9/2/22 | 9/21/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Junio | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0694 | - | - | 0.0202 | 0.0812 | 0.0108 | - | - | - | - | - | - | - |
| EBITDA | - | -4.921 | -6.917 | -6.9 | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | -5.001 | -6.992 | -6.963 | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | -7,208.79% | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -4.733 | -7.478 | -7.743 | - | - | - | - | - | - | - | - | - | - |
| Net income | -6.769 | -4.733 | -7.478 | -7.743 | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | -6,823.35% | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -14.08 | -9.824 | -15.41 | -12.15 | -4.884 | -4.063 | - | -4.345 | -4.039 | -1.214 | -0.6230 | -0.5600 | -0.6070 | -0.7160 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/22 | 5/16/22 | 9/2/22 | 11/10/22 | 2/13/23 | 5/15/23 | 9/21/23 | 11/13/23 | 2/13/24 | - | - | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -23.3 | - | -41.2 | -84.6 | -26.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.02 | - | - | 1.37 | 1.95 |
| Capex / Sales | - | - | - | 17.64% | - | - | - | - |
| Announcement Date | 8/29/19 | 10/6/20 | 9/20/21 | 9/2/22 | 9/21/23 | - | - | - |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
10.58
AUD
Average target price
24.91
AUD
Spread / Average Target
+135.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +113.62% | 17.89M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BNTC Stock
- Financials Benitec Biopharma Inc.
